Sweden's Orexo has entered into an agreement with AstraZeneca ($AZN) regarding OX-CLI, a preclinical program for a new therapy to treat respiratory diseases. Under the agreement, AstraZeneca gains rights from Orexo to conduct further preclinical research and evaluation of compounds in the OX-CLI program. "Our OX-CLI program is a promising R&D project, which has potential to improve the treatment of respiratory diseases for millions of patients," CEO Anders Lundström said in a statement. Article | Release